ArticleEvidence-based complementary and alternative medicine : eCAM2019
Moxibustion Exerts a Neuroprotective Effect through Antiferroptosis in Parkinson's Disease.
Article in Evidence-based complementary and alternative medicine : eCAM, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- From Tradition to Innovation: Acupuncture Therapies Targeting Ferroptosis in Neurological Disorders.Brain and behavior · 2025Pooled it
- Acupuncture-Related Therapies for Parkinson's Disease: A Meta-Analysis and Qualitative Review.Frontiers in aging neuroscience · 2021Pooled it
- Activation of mitophagy via miR-223/NLRP3 axis ameliorates dopaminergic neuronal damage in parkinson's disease.Metabolic brain disease · 2026Article
- Astaxanthin-Loaded Silver Nanoparticles Mitigate 6-OHDA-Induced Parkinson's via ER Stress and PI3K/Akt/mTOR Signaling.Molecular neurobiology · 2025Article
- Study on the mechanism of Wnt/β-catenin pathway mediated by pterostilbene to reduce cerebral ischemia-reperfusion injury.Biomolecules & biomedicine · 2025Article
- Ferritin Hinders Ferroptosis in Non-Tumorous Diseases: Regulatory Mechanisms and Potential Consequences.Current protein & peptide science · 2025Review
- Nrf2 and Ferroptosis: Exploring Translational Avenues for Therapeutic Approaches to Neurological Diseases.Current drug targets · 2025Review
- Moxibustion treatment for Parkinson's disease: study protocol for a randomized controlled trial.BMC complementary medicine and therapies · 2023Article
- Zooming in and out of ferroptosis in human disease.Frontiers of medicine · 2023Review
- Carthamin yellow attenuates brain injury in a neonatal rat model of ischemic-hypoxic encephalopathy by inhibiting neuronal ferroptosis in the hippocampus.Translational neuroscience · 2023Article
- Review
- Effects of electroacupuncture on the functionality of NG2-expressing cells in perilesional brain tissue of mice following ischemic stroke.Neural regeneration research · 2022Article
- Ferroptosis and Its Role in Chronic Diseases.Cells · 2022Review
- Carthamin yellow improves cerebral ischemia‑reperfusion injury by attenuating inflammation and ferroptosis in rats.International journal of molecular medicine · 2021Article
- miR‑335 promotes ferroptosis by targeting ferritin heavy chain 1 inInternational journal of molecular medicine · 2021Article
- Idebenone Ameliorates Rotenone-Induced Parkinson's Disease in Rats Through Decreasing Lipid Peroxidation.Neurochemical research · 2021Article
- Emerging Mechanisms and Disease Implications of Ferroptosis: Potential Applications of Natural Products.Frontiers in cell and developmental biology · 2021Review
- Metabolomics Analysis on Mice With Depression Ameliorated by Acupoint Catgut Embedding.Frontiers in psychiatry · 2021Article
- Ferroptosis as a New Mechanism in Parkinson's Disease Therapy Using Traditional Chinese Medicine.Frontiers in pharmacology · 2021Review
- Moxibustion Protects Dopaminergic Neurons in Parkinson's Disease through Antiferroptosis.Evidence-based complementary and alternative medicine : eCAM · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The objective of this study was to explore the neuroprotective effect of moxibustion on rats with Parkinson's disease (PD) and its mechanism. A Parkinson's disease model was established in rats using a two-point stereotactic 6-hydroxydopamine injection in the right substantia nigra (SN) and ventral tegmental area. The rats received moxibustion at the Baihui (GV20) and Sishencong (EX-HN1) acupoints for 20 minutes, six times a week, for 6 weeks. The right SN tissue was histologically and immunohistochemically examined. Differentially expressed genes (DEGs) were identified through RNA sequencing. In addition, the levels of tyrosine hydroxylase (TH), glutathione peroxidase 4 (GPX4), and ferritin heavy chain 1 (FTH1) in SN were measured. In comparison to the model group, the moxibustion group showed a significantly greater TH immunoreactivity and a higher behavioural score. In particular, moxibustion led to an increase in the number and morphological stability of SN neural cells. The functional pathway analysis showed that DEGs are closely related to the ferroptosis pathway. GPX4 and FTH1 in the SN were significantly overexpressed in the moxibustion-treated rats with PD. Moxibustion can effectively reduce the death of SN neurons, decrease the occurrence of ferroptosis, and increase the TH activity to protect the neurons in rats with PD. The protective mechanism may be associated with suppression of the ferroptosis.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.